Longeveron Inc.
June 13, 2024 - by Joey Ramson
Shares of biotech company $LGVN continue to surge today after yesterdays big move, when the company released Phase 2 trial data of Lomocel-B, a treatment for patients suffering from hypoplastic left heart syndrome.
